Ivan Alquisiras-Burgos is a chemist graduated from the Autonomous University of Guerrero State. He earned his master's degree from the same university and later obtained a Ph.D. in science with a specialization in biomedical sciences from the National Autonomous University of Mexico (UNAM). During his Ph.D., he focused on the field of neurosciences and subsequently undertook a Postdoctoral stay in the Department of Neurosciences at the UNAM Institute of Cellular Physiology. Currently, he serves as a principal investigator at the National Institute of Neurology and Neurosurgery in Mexico City. His primary research interest lies in comprehending the molecular mechanisms involved in neurodegeneration following a cerebral infarction, particularly in the context of aging.

Dr. Irma Gabriela González Herrera is currently a researcher at the National Institute of Neurology and Neurosurgery in Mexico City (https://www.gob.mx/salud/innn). She obtained her bachelor´s degree in Pharmaceutical Biological-Chemistry from the Faculty of Chemistry of the National Autonomous University of Mexico (UNAM) and her Ph.D. in Biotechnology in Health and Life Sciences with a specialty in Molecular and Cellular Physiopathology from the Paul Sabatier University in Toulouse (France).  She subsequently completed a postdoctoral research associate position at the Institute of Biotechnology (UNAM), where she researched the function of stem cells in the mammalian brain. She has been a part of the Mexican Researchers National System since 2007 and obtained French fellowships from the foundation ARC pour la Recherche sur le cancer (2001 and 2002) and from La Ligue Contre le Cancer (2004), and fellowships for the training of high-level human resources (UNAM, 2006) and “Rosalind Franklin, to promote scientific careers for women (Mexico City Institute for Science and Innovation, 2008).

Sergio Alcalá-Alcalá is a Pharmacologist Chemist who completed his master's studies in the Master's program in Chemical Sciences at the National Autonomous University of Mexico (UNAM), in the area of Pharmaceutical Technology. He obtained the degree of Doctor in the Doctorate program in Chemical Sciences of the UNAM. Dr. Alcalá is Associate Research Professor “C” of the Faculty of Pharmacy of the Autonomous University of the state of Morelos (UAEM) since 2015, responsible for the Pharmaceutical Technology Research Laboratory. His working group feeds the research line “Development of Innovative Pharmaceutical Forms”. He currently directs projects based on the development and characterization of unconventional medications based on micro and nanoparticles, liposomes and microemulsions to administer drugs (Class II and IV) indicated for conditions of national interest, using alternative routes of administration; mainly the pulmonary and transdermal route. He has presented more than 15 free papers at national and international conferences. He is a reviewer in more than 5 internationally recognized and refereed journals in the area of pharmaceutical technology.

Penélope Aguilera received a Ph.D. in Science with a specialty in Molecular Biology from the Center for Research and Advanced Studies, National Polytechnic Institute, Mexico. Then, Dr. Aguilera achieved a Postdoctoral stay in the Biochemistry Department of the Royal Holloway & Bedford New College, University of London, England, and worked as an associate researcher in the Neuroscience department of the Institute of Cellular Physiology, National Autonomous University of Mexico (UNAM). Dr. Aguilera is currently a researcher in Medical Sciences at the National Institute of Neurology and Neurosurgery in Mexico City, as Principal Investigator of the Laboratory of Cerebral Vascular Pathology. Dr. Aguilera teaches postgraduate chair at UNAM. Her primary interest is the characterization of signaling pathways that are regulated by antioxidants as part of the endogenous neuroprotection process in cerebral ischemia. In particular, she focuses on those pathways involved with energy metabolism, glutamate neurotoxicity, and edema formation. She uses the experimental model of in vivo brain infarction, which is induced by the occlusion of the middle cerebral rat brain artery, and the in vitro model of oxygen and glucose deprivation in primary neuronal cultures and cerebral microvascular micro endothelium cell line.